Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation ✅
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 07, 2021 7:37am
170 Views
Post# 33150499

RE:RE:RE:Amalgamation ✅

RE:RE:RE:Amalgamation ✅
AntibeTribe wrote:
MrMugsy wrote:
OakTreeforest39 wrote: Hope for the best


Hahaha!  It did come through this week !!!

11.4 percent dilution ... better than the 13-15% I was expecting.
Insiders still have a lot of control to fend off any hostile attack.

OK - what's next ?


... Mugs, you are like a Gypsy Woman, I swear! Do you do any other sort of future telling? Palm reading? Number picking? Birthday guessing ? Lol! But in all seriousness, great call on this timing. Well done!


Hahaha.  Thanks AntibeTribe.
I really do suck at guessing the share price though - never mastered that ... hahaha!
I do think we will have a run on share price before we go to the NASDAQ - assuming the markets play nice.
That would mean ... the summer lead-up to P3 and NASDAQ should be fun !!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities